Survey on Epidemiology of Hypoparathyroidism in France
Epi-Hypo
Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France
1 other identifier
observational
3,000
1 country
57
Brief Summary
Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
Longer than P75 for all trials
57 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 9, 2016
CompletedFirst Posted
Study publicly available on registry
July 20, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2031
September 24, 2024
September 1, 2024
14.2 years
July 9, 2016
September 22, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of the epidemiology of patients with hypoparathyroidism in France
Data collected by questionnaire about etiology of hypoparathyroidism, filled by physicians from clinic folders
Through study completion, about 2 years
Secondary Outcomes (3)
Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion)
At inclusion (under treatment): through study completion, about 2 years
Assessment of the management at inclusion will describe treatment and complications at inclusion
At inclusion (under treatment): through study completion, about 2 years
Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population
Through study completion, about 2 years
Other Outcomes (1)
Assessment of the physician's management will help describing the habits of french physician who manage hypoparathyroidism in terms of follow-up
At inclusion
Study Arms (1)
Hypoparathyroidism
No intervention.
Interventions
Eligibility Criteria
All patients for whom hypoparathyroidism is diagnosed in France
You may qualify if:
- patient fro whom chronic hypoparathyroidism is diagnosed
- patient living in France
You may not qualify if:
- patient who does not want his data to be collected in this registry
- pseudo-hypoparathyroidism
- acute hypoparathyroidism
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (57)
Felix Guyon Hospital
Saint-Denis, La Réunion, France
Hôpital Privé de Provence
Aix-en-Provence, 13100, France
Amiens University Hospital
Amiens, 80054, France
Clinic Auch Area
Auch, France
Henri Mondor Hospital
Aurillac, France
Jean Minjoz Hospital
Besançon, France
Blanquefort
Blanquefort, France
Avicenne Hospital, AP-HP
Bobigny, 93000, France
Jean Verdier Hospital, AP-HP
Bondy, France
University Hospital
Bordeaux, France
Bourgoin Jallieu Hospital
Bourgoin, France
La Cavale Blanche Hospital
Brest, France
Côte de Nacre Hospital
Caen, France
Henri Mondor Hospital, APHP
Créteil, France
Dax-Côte d'Argent Hospital
Dax, France
University Hospital
Dijon, France
Grenoble Alpes Hospital
Grenoble, France
CHD Vendée
La Roche-sur-Yon, 85925, France
Kremlin-Bicêtre Hospital, APHP
Le Kremlin-Bicêtre, France
Le Mans Hospital
Le Mans, France
Libourne Hospital
Libourne, France
Claude Huriez Hospital
Lille, France
Edouard Herriot Hospital, HCL
Lyon, France
La Conception Hospital, AP-HM
Marseille, France
Clinic Metz Area
Metz, France
Mercy Hospital
Metz, France
Clinic area
Mérignac, France
Arnaud de Villeneuve Hospital
Montpellier, France
Brabois Hospital
Nancy, France
University Hospital
Nantes, France
University Hospital
Nice, 06200, France
Georges Renon Hospital
Niort, 79000, France
Caremeau Hospital
Nîmes, France
European Georges Pompidou Hospital, APHP
Paris, 75908, France
Clinic Paris Area
Paris, France
Cochin Hospital, APHP
Paris, France
Lariboisière Hospital, APHP
Paris, France
Necker Hospital, AP-HP
Paris, France
Pitié-Salpêtrière Hospital, APHP
Paris, France
Saint-Louis Hospital, AP-HP
Paris, France
Tenon Hospital, APHP
Paris, France
Passy Hospital
Passy, France
Clinic Poitiers Area
Poitiers, France
Laennec Hospital
Quimper, France
Reims University Hospital
Reims, France
Clinic Rennes Area
Rennes, France
Charles Nicolle Hospital
Rouen, France
Saint Florent Le Vieil
Saint-Florent-le-Vieil, France
Clinic Area
Saint-Junien, 87200, France
Clinique du Landy
Saint-Ouen, France
Hautepierre Hospital
Strasbourg, France
Sainte Anne Hospital, HIA
Toulon, France
Larrey Hospital
Toulouse, France
Guy Chatiliez Hospital
Tourcoing, France
Bretonneau Hospital
Tours, France
Valenciennes Hospital
Valenciennes, France
CHIV - Lucie et Raymond Aubrac
Villeneuve-Saint-Georges, France
Related Publications (1)
Bertocchio JP, Grosset N, Groussin L, Kamenicky P, Larceneux F, Lienhardt-Roussie A, Linglart A, Maruani G, Mirallie E, Pattou F, Seervai RNH, Sido C, Silve C, Vilfaillot A, Tabarin A, Vantyghem MC, Houillier P. Practice patterns for chronic hypoparathyroidism: data from patients and physicians in France. Endocr Connect. 2022 Jan 31;11(1):e210350. doi: 10.1530/EC-21-0350.
PMID: 34939939RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Philippe Bertocchio, MD, PhD
European Georges Pompidou Hospital, APHP
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 20 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
July 9, 2016
First Posted
July 20, 2016
Study Start
July 1, 2016
Primary Completion (Estimated)
September 1, 2030
Study Completion (Estimated)
September 1, 2031
Last Updated
September 24, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share